DGAP-News: Genmab Announces Financial Results for the First Half of 2013 and Improves 2013 Financial Guidance

ID: 1254725
recent pressrelease next pressrelease

(businesspress24) - Genmab A/S

14.08.2013 17:08
---------------------------------------------------------------------------

August 14, 2013; Copenhagen, Denmark;
Interim Report First Half 2013

-- Reported positive top line results in Phase III study of ofatumumab in
previously untreated chronic lymphocytic leukemia (CLL)
-- Received Breakthrough Therapy Designation for daratumumab
-- First half net sales of Arzerra(r) increased 40% over prior year
-- Improved operating result by DKK 93 million over H1 2012
-- Improved guidance and year-end cash balance

'The strength and value of our pipeline is becoming very clear as we achieve
our goals with ofatumumab and daratumumab. We reported two strong sets of data
on ofatumumab in chronic lymphocytic leukemia during the second quarter which
show the future promise of this therapy. We were also very pleased that
daratumumab was awarded Breakthrough Therapy Designation by the FDA, which we
hope will expedite bringing this treatment to the market. These achievements,
together with our improved financial guidance, continue to move Genmab forward
to our goal of becoming sustainably profitable,' said Jan van de Winkel, Ph.D.,
Chief Executive Officer of Genmab.

Financial Performance First Half

-- Genmab's revenue was DKK 298 million for the first half of 2013 compared to
DKK 206 million for the corresponding period in 2012. The increase of DKK
92 million or 45% was mainly driven by revenue related to our daratumumab
collaboration with Janssen Biotech (Janssen) as well as higher Arzerra
royalties.
-- Operating expenses were unchanged at DKK 287 million compared to the first
half of 2012.
-- Operating income was DKK 11 million in the first half of 2013 compared to
an operating loss of DKK 82 million in the corresponding period for 2012,


an improvement of DKK 93 million. The improved operating result was driven
by increased revenue and continued strong focus on cost control.
-- The net result for discontinued operation amounted to a net income of DKK
42 million in the first half of 2013. The net income in 2013 related to the
final few months of running costs of the Minnesota manufacturing facility
of DKK 10 million prior to its divestiture and a gain on the sale of DKK 52
million. The facility maintenance cost amounted to DKK 20 million in the
first half of 2012.
-- On June 30, 2013, Genmab had a cash position of DKK 1,547 million. This
represented a net increase of DKK 31 million from the beginning of 2013
which was primarily related to proceeds from the sale of the manufacturing
facility and proceeds from the exercise of warrants in the first half of
2013, partially offset by the ongoing investment in our research and
development activities. The cash burn for the first half of 2012 was DKK
153 million.

Business Progress Second Quarter to Present

-- April&May: The US Food and Drug Administration (FDA) granted
Breakthrough Therapy, Fast Track and Orphan Drug Designations for
daratumumab. The designations cover patients with multiple myeloma who have
received at least three prior lines of therapy including a proteasome
inhibitor (PI) and an immunomodulatory agent (IMiD) or are double
refractory to a PI and an IMiD.
-- April: The US Court of Appeals for the Federal Circuit upheld the US
District Court's judgment in favor of GSK in a patent infringement case
involving Arzerra brought against GSK by Genentech and Biogen Idec. A
request for a re-hearing was filed by Genentech and Biogen Idec in May and
subsequently refused by the US Court of Appeals in July.
-- May: Reported positive top line data from a Phase II study of ofatumumab in
combination with bendamustine in patients with untreated or relapsed CLL.
The overall response rate (ORR) in the study was 95% in previously
untreated patients and 74% in patients with relapsed CLL.
-- May: Reported positive top line results from a Phase III study of
ofatumumab in combination with chlorambucil versus chlorambucil alone in
patients with previously untreated CLL. A 9.3 month improvement in median
progression free survival (PFS) was seen in patients who received
ofatumumab and chlorambucil compared to patients who received chlorambucil
alone.
-- May: Launched Sponsored Level 1 American Depositary Receipt (ADR Program)
under the ticker symbol GMXAY.
-- June: Phase II development of teprotumumab (RG1507, an antibody created by
Genmab in collaboration with Roche) in active thyroid eye disease was
restarted by River Vision Development Corporation, who licensed the product
from Roche.
-- July: A Phase III study of ofatumumab given subcutaneously to treat
pemphigus vulgaris (PV), a rare autoimmune disorder of the skin, is being
started by GSK.
-- July: Filed an Investigational New Drug application (IND) with the US FDA
for HuMax(r)-TF-ADC in solid tumors.
-- July: GSK reported net sales for Arzerra for the second quarter of 2013 of
GBP 17.8 million, an increase of 19% over Q2 2012, resulting in royalty
income of DKK 31 million to Genmab.

Outlook
Genmab is improving its 2013 financial guidance as announced on March 7, 2013.

Conference Call
Genmab will hold a conference call in English to discuss the results for the
first half of 2013 today, Wednesday, August 14, at 6.00 pm CEST, 5.00 pm BST or
noon EDT. The dial in numbers are:

+1 866 682 8490 (US participants) and ask for the Genmab conference call
+44 1452 555 131 (international participants) and ask for the Genmab conference
call

A live and archived webcast of the call and relevant slides will be available
at www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations&Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen(at)genmab.com

This interim report contains forward looking statements. The words 'believe',
'expect', 'anticipate', 'intend' and 'plan' and similar expressions identify
forward looking statements. Actual results or performance may differ materially
from any future results or performance expressed or implied by such statements.
The important factors that could cause our actual results or performance to
differ materially include, among others, risks associated with product
discovery and development, uncertainties related to the outcome and conduct of
clinical trials including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our products, our
inability to manage growth, the competitive environment in relation to our
business area and markets, our inability to attract and retain suitably
qualified personnel, the unenforceability or lack of protection of our patents
and proprietary rights, our relationships with affiliated entities, changes and
developments in technology which may render our products obsolete, and other
factors. For a further discussion of these risks, please refer to the section
'Risk Management' in Genmab's annual report, which is available on
www.genmab.com and the 'Significant Risks and Uncertainties' section in this
interim report. Genmab does not undertake any obligation to update or revise
forward looking statements in this interim report nor to confirm such
statements in relation to actual results, unless required by law.

Genmab A/Sand its subsidiaries own the following trademarks: Genmab(r); the
Y-shaped Genmab logo(r); Genmab in combination with the Y-shaped Genmab logo(tm);
the DuoBody(tm) logo; HuMax(r); HuMax-CD20(r); DuoBody(r), HexaBody(TM) and UniBody(r).
Arzerra(r) is a registered trademark of GlaxoSmithKline.

Company Announcement no. 34
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark

Click on, or paste the following link into your web browser, to view the associated documents

https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=441050

News Source: NASDAQ OMX



14.08.2013 Dissemination of a Corporate News, transmitted by DGAP -
a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: Genmab A/S


Denmark
Phone:
Fax:
E-mail:
Internet:
ISIN: DK0010272202
WKN:

End of Announcement DGAP News-Service

---------------------------------------------------------------------------



Keywords (optional):

genmab-announces-financial-results-for-the-first-half-of-2013-and-improves-2013-financial-guidance,



Company information / Profile:

PressRelease by

Requests:



PressContact / Agency:



published by: EquityStory
print pressrelease  send to a friend  

Date: 08/14/2013 - 11:08
Language: English
News-ID 1254725
Character count: 0
Kontakt-Informationen:
Firma: Genmab A/S
Ansprechpartner: Feedback to businesspress24.com about Pressrelease-id:
Stadt:
Telefon:

Comments:



Number of hits: 181

Linking-Tips:



Direct Link to this PressRelease:






We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease






All members: 9 437
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 53


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.